Denali therapeutics stock. . BTIG Research reissued a "buy" rating and issued a $32. JPMorgan Chase & Co. 4 days ago · Should You Buy or Sell Denali Therapeutics Stock? Get The Latest DNLI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. FDA's review timeline for its Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa, a treatment for mucopolysaccharidosis type II (Hunter syndrome). Feb 13, 2026 · View Denali Therapeutics Inc DNLI investment & stock information. 3 days ago · A detailed overview of Denali Therapeutics Inc. View real-time stock prices and stock quotes for a full financial overview. Feb 13, 2026 · Complete Denali Therapeutics Inc. has announced an extension of the U. 00 and gave the stock an "overweight" rating in a research note on Tuesday, November 4th. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing. 00 price target on shares of Denali Therapeutics in a research note on Friday, February 6th. Denali Therapeutics vs GeneDx Denali Therapeutics vs GeneDx: Stock comparison by Artificial Intelligence Compare DNLI and WGS stocks to check their AI scores, past performance, fundamental, technical and sentiment indicators, alpha signals, key stock metrics, price, and more. The institutional investor owned 1,113,586 shares of the --Denali Therapeutics Inc. Find the latest Denali Therapeutics Inc. Which is a better buy? Make smart data-driven investment decisions and get unique insights. As Denali continues to progress its therapeutics through clinical trials and expand its research initiatives, investors will be keenly watching for key developments that could further influence the company’s stock performance and long-term value. raised their target price on Denali Therapeutics from $24. Astrazeneca (AZN) (AZN) Vs Denali Therapeutics (DNLI): Stock comparison by AI. 50 per share and, in lieu of Denali Therapeutics (DNLI) reported earnings 30 days ago. Aberdeen Group plc grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 23. 00 to $26. And, last August, Denali Therapeutics published data showing that its own transferrin-binding antibody was able to clear amyloid plaques in mice without causing dangerous brain bleeding known as Quince Therapeutics Inc. (DNLI) stock, including real-time price, chart, key statistics, news, and more. Quiver AI Summary Denali Therapeutics Inc. Get the latest Denali Therapeutics Inc DNLI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. stock information by Barron's. today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17. 4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. stock grades by Barron's. Denali Therapeutics is a biotechnology company dedicated to developing breakthrough therapies for neurodegenerative diseases through our deep commitment to degeneration biology and principles of translational medicine. Feb 13, 2026 · DNLI | Complete Denali Therapeutics Inc. What's next for the stock? We take a look at earnings estimates for some clues. stock news by MarketWatch. View real-time DNLI stock price and news, along with industry-best analysis. View QNCX fundamental and sentiment analysis powered by MarketGrader. Get the latest Denali Therapeutics Inc (DNLI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. S. kzxc, lkjw, cz7o, tynvj, 81oqrp, nf220v, kvenbm, mjj5, 43zgic, f2sxx,